scholarly journals Peroxisome Proliferator–Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling

2016 ◽  
Vol 54 (1) ◽  
pp. 136-146 ◽  
Author(s):  
Bum-Yong Kang ◽  
Kathy K. Park ◽  
Jennifer M. Kleinhenz ◽  
Tamara C. Murphy ◽  
David E. Green ◽  
...  
2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Hsu-Lung Jen ◽  
Po-Len Liu ◽  
Yung-Hsiang Chen ◽  
Wei-Hsian Yin ◽  
Jaw-Wen Chen ◽  
...  

Peroxisome proliferator-activated receptorα(PPARα) plays a role in the pathogenesis of cardiac hypertrophy, although its underlying mechanism remains unclear. The purpose of this study was to evaluate the effect of PPARαactivation on endothelin-1- (ET-1-) caused cardiomyocyte hypertrophy and explore its underlying mechanisms. Human cardiomyocytes (HCMs) were cultured with or without ET-1, whereafter the inhibitory effects of fenofibrate, a PPARαactivator, on cell size and adiponectin protein were tested. We examined the activation of extracellular signal-regulated kinase (ERK) and p38 proteins caused by ET-1 and the inhibition of the ERK and p38 pathways on ET-1-induced cell size and adiponectin expression. Moreover, we investigated the interaction of PPARαwith adiponectin and nuclear factor-κB (NF-κB) by electrophoretic mobility shift assays and coimmunoprecipitation. ET-1 treatment significantly increased cell size, suppressed PPARαexpression, and enhanced the expression of adiponectin. Pretreatment with fenofibrate inhibited the increase in cell size and enhancement of adiponectin expression. ET-1 significantly activated the ERK and p38 pathways, whereas PD98059 and SB205380, respectively, inhibited them. Our results suggest that activated PPARαcan decrease activation of adiponectin and NF-κB and inhibit ET-1-induced cardiomyocyte hypertrophy.


2020 ◽  
Vol 34 (3) ◽  
pp. 4283-4292
Author(s):  
Sydney L. Lane ◽  
Alexandrea S. Doyle ◽  
Elise S. Bales ◽  
Julie A. Houck ◽  
Ramón A. Lorca ◽  
...  

2002 ◽  
Vol 103 (s2002) ◽  
pp. 16S-20S ◽  
Author(s):  
Satoshi SAKAI ◽  
Takashi MIYAUCHI ◽  
Yoko IRUKAYAMA-TOMOBE ◽  
Takehiro OGATA ◽  
Katsutoshi GOTO ◽  
...  

Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo. Peroxisome proliferator-activated receptor γ (PPARγ), a member of the family of nuclear receptors, suppresses activator protein-1 (AP-1). We investigated the effects of the thiazolidinediones troglitazone and pioglitazone, activators of PPARγ, on cardiac hypertrophy due to pressure overload provoked by abdominal aortic banding (AB) in rats. Rats were divided into four groups: sham operation with vehicle treatment (n = 5); AB surgery with vehicle treatment (n = 6); AB surgery with troglitazone treatment (100mg·kg-1·day-1; n = 5); and AB surgery with pioglitazone treatment (10mg·kg-1·day-1; n = 8). Treatments were started 7 days before AB surgery, and left ventricular (LV) hypertrophy was assessed 24h after surgery. The ratio of LV weight/body weight (BW) was significantly increased in AB rats compared with sham-operated rats; treatment of AB rats with troglitazone or pioglitazone significantly inhibited the increase in LV weight/BW. Expression of ET-1 mRNA was markedly enhanced in the left ventricles of AB rats; treatment with troglitazone or pioglitazone lowered expression significantly. Suppression of cardiac hypertrophy by pioglitazone treatment was accompanied by a decrease in expression of the gene encoding brain natriuretic factor, a molecular marker for cardiac hypertrophy, in AB rats. Because the ET-1 gene has AP-1 response elements in its 5´-flanking region, the thiazolidinediones troglitazone and pioglitazone may inhibit cardiac hypertrophy partly through suppression of AP-1-induced ET-1 gene up-regulation.


Sign in / Sign up

Export Citation Format

Share Document